citing issues with a third-party supplier. Given the substantial fall in Regeneron’s stock price, the natural question arises: is REGN now an attractive buying opportunity? From a valuation ...

The decision follows recent challenges faced by the company, including the failure of itepekimab and ongoing issues ... stock decline, but analysts still see long-term value in Regeneron’s ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The decision follows recent challenges faced by the company, including the failure of itepekimab and ongoing issues with the Eylea ... results led to a notable stock decline, but analysts still see ...

The updated guidance assumes that Dollar General will be able to mitigate "a significant portion of the potential impact to its cost of goods from tariffs at currently implemented rates," the company ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Verizon ...

The updated guidance assumes that Dollar General will be able to mitigate "a significant portion of the potential impact to its cost of goods from tariffs at currently implemented rates," the company ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...